Reprogramming cancer immunity with next-generation combination therapies
Cancer immunotherapy has fundamentally reshaped oncology by harnessing the immune system to eliminate malignant cells. Immune checkpoint inhibitors targeting CTLA-4 and PD-1/PD-L1 have achieved durable remissions in select cancers, yet most patients exhibit resistance due to tumor heterogeneity, imm...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
28 August 2025
|
| In: |
Frontiers in cell and developmental biology
Year: 2025, Jahrgang: 13, Pages: 1-15 |
| ISSN: | 2296-634X |
| DOI: | 10.3389/fcell.2025.1652047 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.3389/fcell.2025.1652047 Verlag, kostenfrei, Volltext: https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2025.1652047/full 
|
| Verfasserangaben: | Nikolaos C. Kyriakidis, Carolina E. Echeverría, Jhommara Bautista, Sebastián Rivera-Orellana, María José Ramos-Medina, Camila Salazar-Santoliva, Juan S. Izquierdo-Condoy, Esteban Ortiz-Prado, Santiago Guerrero and Andrés López-Cortés |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1961001489 | ||
| 003 | DE-627 | ||
| 005 | 20260213115116.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 260213s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fcell.2025.1652047 |2 doi | |
| 035 | |a (DE-627)1961001489 | ||
| 035 | |a (DE-599)KXP1961001489 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 32 |2 sdnb | ||
| 100 | 1 | |a Kyriakidis, Nikolaos C. |e VerfasserIn |0 (DE-588)1390128679 |0 (DE-627)1961003074 |4 aut | |
| 245 | 1 | 0 | |a Reprogramming cancer immunity with next-generation combination therapies |c Nikolaos C. Kyriakidis, Carolina E. Echeverría, Jhommara Bautista, Sebastián Rivera-Orellana, María José Ramos-Medina, Camila Salazar-Santoliva, Juan S. Izquierdo-Condoy, Esteban Ortiz-Prado, Santiago Guerrero and Andrés López-Cortés |
| 264 | 1 | |c 28 August 2025 | |
| 300 | |b Illustrationen | ||
| 300 | |a 15 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 13.02.2026 | ||
| 520 | |a Cancer immunotherapy has fundamentally reshaped oncology by harnessing the immune system to eliminate malignant cells. Immune checkpoint inhibitors targeting CTLA-4 and PD-1/PD-L1 have achieved durable remissions in select cancers, yet most patients exhibit resistance due to tumor heterogeneity, immunometabolic rewiring, and the immunosuppressive tumor microenvironment. To address these limitations, next-generation immunotherapies have emerged, targeting multiple layers of immune regulation. These include co-inhibitory and co-stimulatory checkpoint modulators, bispecific antibodies, adoptive cell therapies, cancer vaccines, oncolytic viruses, cytokine-based strategies, and synthetic immunomodulators that activate innate sensors. Nanotechnology and in vivo immune engineering further enhance specificity, reduce toxicity, and broaden applicability. Combination immunotherapy has become central to overcoming resistance, with rational regimens integrating ICIs, cytokines, vaccines, and targeted agents. Biomarker-guided strategies, leveraging tumor mutational burden, immune cell infiltration, and multi-omic profiling, are enabling personalized approaches. However, immune-related adverse events and variability in therapeutic responses necessitate predictive biomarkers and improved patient stratification. Emerging frontiers include microbiome-targeted interventions, chronotherapy, and AI-driven modeling of tumor-immune dynamics. Equally critical is ensuring global equity through inclusive trial design, diverse biomarker validation, and expanded access to cutting-edge therapies. This review provides a comprehensive analysis of multimodal immunotherapeutic strategies, their mechanistic basis, and clinical integration. By unifying innovation in immunology, synthetic biology, and systems medicine, next-generation cancer immunotherapy is poised to transition from a transformative intervention to a curative paradigm across malignancies. | ||
| 650 | 4 | |a adoptive cell therapy | |
| 650 | 4 | |a biomarker-guided precision medicine | |
| 650 | 4 | |a cancer immunotherapy | |
| 650 | 4 | |a immune checkpoints | |
| 650 | 4 | |a next-generation therapeutics | |
| 650 | 4 | |a tumor microenvironment | |
| 700 | 1 | |a Echeverría, Carolina E. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bautista, Jhommara |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rivera-Orellana, Sebastián |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ramos Medina, María José |e VerfasserIn |0 (DE-588)136069725X |0 (DE-627)1920191755 |4 aut | |
| 700 | 1 | |a Salazar-Santoliva, Camila |e VerfasserIn |4 aut | |
| 700 | 1 | |a Izquierdo-Condoy, Juan S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ortiz-Prado, Esteban |e VerfasserIn |4 aut | |
| 700 | 1 | |a Guerrero, Santiago |e VerfasserIn |4 aut | |
| 700 | 1 | |a López-Cortés, Andrés |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in cell and developmental biology |d Lausanne : Frontiers Media, 2013 |g 13(2025), Artikel-ID 1652047, Seite 1-15 |h Online-Ressource |w (DE-627)770398138 |w (DE-600)2737824-X |w (DE-576)394650182 |x 2296-634X |7 nnas |a Reprogramming cancer immunity with next-generation combination therapies |
| 773 | 1 | 8 | |g volume:13 |g year:2025 |g elocationid:1652047 |g pages:1-15 |g extent:15 |a Reprogramming cancer immunity with next-generation combination therapies |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fcell.2025.1652047 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |7 0 |
| 856 | 4 | 0 | |u https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2025.1652047/full |x Verlag |z kostenfrei |3 Volltext |7 0 |
| 951 | |a AR | ||
| 992 | |a 20260213 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 136069725X |a Ramos Medina, María José |m 136069725X:Ramos Medina, María José |d 140000 |e 140000PR136069725X |k 0/140000/ |p 5 | ||
| 999 | |a KXP-PPN1961001489 |e 4915998223 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"family":"Kyriakidis","given":"Nikolaos C.","display":"Kyriakidis, Nikolaos C.","role":"aut"},{"role":"aut","display":"Echeverría, Carolina E.","given":"Carolina E.","family":"Echeverría"},{"role":"aut","display":"Bautista, Jhommara","given":"Jhommara","family":"Bautista"},{"display":"Rivera-Orellana, Sebastián","role":"aut","family":"Rivera-Orellana","given":"Sebastián"},{"family":"Ramos Medina","given":"María José","display":"Ramos Medina, María José","role":"aut"},{"role":"aut","display":"Salazar-Santoliva, Camila","family":"Salazar-Santoliva","given":"Camila"},{"family":"Izquierdo-Condoy","given":"Juan S.","display":"Izquierdo-Condoy, Juan S.","role":"aut"},{"role":"aut","display":"Ortiz-Prado, Esteban","given":"Esteban","family":"Ortiz-Prado"},{"display":"Guerrero, Santiago","role":"aut","given":"Santiago","family":"Guerrero"},{"family":"López-Cortés","given":"Andrés","role":"aut","display":"López-Cortés, Andrés"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"id":{"doi":["10.3389/fcell.2025.1652047"],"eki":["1961001489"]},"note":["Gesehen am 13.02.2026"],"origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"28 August 2025"}],"name":{"displayForm":["Nikolaos C. Kyriakidis, Carolina E. Echeverría, Jhommara Bautista, Sebastián Rivera-Orellana, María José Ramos-Medina, Camila Salazar-Santoliva, Juan S. Izquierdo-Condoy, Esteban Ortiz-Prado, Santiago Guerrero and Andrés López-Cortés"]},"relHost":[{"id":{"issn":["2296-634X"],"zdb":["2737824-X"],"eki":["770398138"]},"disp":"Reprogramming cancer immunity with next-generation combination therapiesFrontiers in cell and developmental biology","language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"title":[{"title_sort":"Frontiers in cell and developmental biology","title":"Frontiers in cell and developmental biology"}],"physDesc":[{"extent":"Online-Ressource"}],"pubHistory":["2013 -"],"part":{"extent":"15","pages":"1-15","text":"13(2025), Artikel-ID 1652047, Seite 1-15","year":"2025","volume":"13"},"titleAlt":[{"title":"FCELL"}],"note":["Gesehen am 04.06.20"],"recId":"770398138","origin":[{"publisherPlace":"Lausanne","dateIssuedKey":"2013","publisher":"Frontiers Media","dateIssuedDisp":"2013-"}]}],"physDesc":[{"extent":"15 S.","noteIll":"Illustrationen"}],"recId":"1961001489","title":[{"title_sort":"Reprogramming cancer immunity with next-generation combination therapies","title":"Reprogramming cancer immunity with next-generation combination therapies"}]} | ||
| SRT | |a KYRIAKIDISREPROGRAMM2820 | ||